The rate of TP53 mutations in our study was significantly higher in patients with KMT2Awt compared to KMT2Ar AML (17.8% vs. 7.9%; p < 0.0001), which correlates with the literature [63]. This evidence concerns the gene TP53 and acute myeloid leukemia.